METHOTREXATE AND PROTON PUMP INHIBITORS: ARE THERE ANY NEGATIVE PHARMACOLOGIAL EFFECTS?

Methotrexate (MTX) is the first-line medication to treat rheumatoid arthritis (RA). However, it may have serious adverse effects (AE) on liver, kidneys, hematopoietic system, etc., thus requiring meticulous control over patient’s condition and the dynamics of laboratory indicators. A number of drugs may affect MT pharmacokinetics and increase its toxicity. In theory, proton pump inhibitors (PPIs) may have this effect. Objective. To assess the relationship between the coadministration of MT and PPIs and the risk for developing drug-induced complications.
Material and Methods. A retrospective analysis of clinical symptoms and laboratory indicators in 539 RA patients (median age, 52.5±14.6 years; 86.8% females and 13.2% males) who received MTX in 2009–2011 was carried out. Fifty-two patients who received PPIs on a regular basis were included in the study. The control group consisted of 104 PPI-naive patients comparable in terms of gender, age, and therapy. The numbers of patients with increased levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), alkaline phosphatase (ALP); anemia (hemoglobin level < 110 g/l in females and <120 g/l in males), leukopenia (<4.0•109/l), elevated creatinine level, and proteinurea (qualitative and quantitative values) were compared.
Results. No significant intergroup differences were revealed. MTX showed no clinically manifested AE. The odds ratio (OR) and 95% confidence interval (CI) for changes in laboratory indicators were as follows: ALT 1.35 (95% CI 0.22–8.32), AST 0.66 (95% CI 0.13–3.38), ALP 0.98 (95% CI 0.955–1.01), anemia 1.19 (95% CI 0.517–2.71), and proteinurea 1.95 (95% CI 0.83–4.59; р=0.17). A small increase in the creatinine level was observed in one case for each group.
Conclusions. The results showed no significant increase in toxicity when low doses of MTX and PPIs were coadministered in RA patients. There was a trend towards more frequent proteinurea in patients who received both drugs. This fact requires further research.

1. <div><p>Насонов ЕЛ. Метотрексат. Перспективы применения в медицине. Москва: Филоматис; 2005. [Nasonov EL. Metotreksat. Perspektivy primeneniya v meditsine. Moscow: Filomatis; 2005.]</p><p>Муравьев ЮВ, Елоева НВ, Лебедева ВВ, Насонов ЕЛ. Современная практика лечения метотрексатом ревматоидного артрита. Научно-практическая ревматология. 2012;53(4):96–7. [Muravyev YV, Eloyeva NV, Lebedeva VV, Nasonov EL. Current practice of methotrexate treatment for rheumatoid arthritis. Rheumatology Science and Practice. 2012;53(4):96–7.]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-1120.</p><p>Муравьев ЮВ. Практическое применение метотрексата при ревматоидном артрите. Клиническая фармакология и терапия. 2010;19(1):91–6. [Murav'ev YuV. Prakticheskoe primenenie metotreksata pri revmatoidnom artrite. Klinicheskaya farmakologiya i terapiya. 2010;19(1):91–6.]</p><p>www.SpecialtyPharmacytimes.com [Internet]. Horn J, Hansten P. Methotrexate and Proton Pump Inhibitors. Published Online: Monday, April 9, 2012. Available from: http://www.pharmacytimes.com/publications/issue/2012/April2012/Methotrexate-and-Proton-Pump-Inhibitors</p><p>Mikkelsen TS, Thorn CF, Yang JJ, et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011 Oct;21(10):679–86. DOI: 10.1097/FPC.0b013e328343dd93.</p><p>Ranchon F, Vantard N, Gouraud A, et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed? Chemotherapy. 2011;57(3):225–9. DOI: 10.1159/000327372. Epub 2011 May 18.</p><p>Santucci R, Levêque D, Kemmel V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res. 2010 Mar;30(3):963–5.</p><p>Suzuki K, Doki K, Homma M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44–9. DOI: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17.</p><p>Joerger M, Huitema AD, van den Bongard HJ, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol. 2006 Jul;62(1):71–80. DOI: http://dx.doi.org/10.1111/j.1365-2125.2005.02513.x.</p><p>Vakily M, Amer F, Kukulka MJ, Andhivarothai N. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J Clin Pharmacol. 2005 Oct;45(10):1179–86. DOI: http://dx.doi.org/10.1177/0091270005280100.</p><p>Bezabeh S, Mackey AC, Kluetz P, et al. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012;17(4):550–4. DOI: 10.1634/theoncologist.2011-0431. Epub 2012 Apr 3.</p><p>New Safety Information: Interaction of Proton Pump Inhibitors (PPIs) with Methotrexate. Information Update. 2012-157 October 19, 2012. Available from: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_157-eng.php</p><p>rlsnet.ru [интернет]. Метотрексат (Methotrexate): инструкция, применение и формула [доступ 17.09.2013]. Доступ по ссылке: http://www.rlsnet.ru/mnn_index_id_955.htm. [rlsnet.ru [internet]. Metotreksat (Methotrexate): instruktsiya, primenenie i formula [dostup 17.09.2013]. Available from: http://www.rlsnet.ru/mnn_index_id_955.htm</p><p>Colebatch AN, Marks JL, van der Heijde DM, Edwards CJ. Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012 Sep;90:62–73. DOI: 10.3899/jrheum.120345.</p><p>Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother. 1992 Feb;26(2):234–7.</p><p>Ahern M, Booth J, Loxton A, et al. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol. 1988 Sep;15(9):1356–60.</p><p>Skeith KJ, Russell AS, Jamali F, et al. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. J Rheumatol. 1990 Aug;17(8):1008–10.</p><p>Hübner G, Sander O, Degner FL, et al. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1997 May;24(5):845–51.</p><p>Schwartz JI, Agrawal NG, Wong PH, et al. Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol. 2009 Oct;49(10):1202–9. DOI: 10.1177/0091270009338939.</p><p>Colebatch AN, Marks JL, Edwards CJ. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008872. DOI: 10.1002/14651858.CD008872. pub2.</p></div><br />